Robert Michael Dudley Transcode Therapeutics, Inc. (RNAZ) insider trading activity

Robert Michael Dudley is Chief Executive Officer of Transcode Therapeutics, Inc.. Currently has a direct ownership of 180,262 shares of RNAZ, which is worth approximately $55,881. The most recent transaction as insider was on Sep 28, 2023, when has been sold 98,000 shares (Common Stock) at a price of $0.51 per share, resulting in proceeds of $49,980. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 180K

0% 3M change

119.13% 12M change

Total Value Held $55,881

Robert Michael Dudley Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Sep 28 2023	BUY Open market or private purchase	$49,980 $0.51 p/Share	98,000 Added 35.22%	180,262 Common Stock
Jun 21 2023	BUY Open market or private purchase	$31,800 $2.65 p/Share	12,000 Added 12.73%	82,262 Common Stock
Jun 20 2023	BUY Open market or private purchase	$16,847 $2.55 p/Share	6,607 Added 8.6%	70,262 Common Stock
Jun 09 2023	BUY Open market or private purchase	$52,439 $2.76 p/Share	19,000 Added 2.04%	912,114 Common Stock
Sep 14 2022	BUY Open market or private purchase	$23,000 $1.15 p/Share	20,000 Added 2.19%	893,114 Common Stock
May 31 2022	BUY Open market or private purchase	$3,740 $1.87 p/Share	2,000 Added 0.23%	873,114 Common Stock
May 27 2022	BUY Open market or private purchase	$51,520 $1.84 p/Share	28,000 Added 3.11%	871,114 Common Stock

RMD

Robert Michael Dudley

Chief Executive Officer

Boston, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RNAZ shares.

Notify only if

Value

Insider Trading

Get notified when an Transcode Therapeutics, Inc. insider buys or sells RNAZ shares.

Notify only if

Operation

Value

Type

News

Receive news related to Transcode Therapeutics, Inc.

Track Activities on RNAZ

Account